Loading
A phase 1/2 trial of Pembrolizumab, Carboplatin, Pemetrexed and Ifinatamab deruxtecan in non-small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) is a phase 1/2 interventional study registered as NCT04165070 by Merck Sharp & Dohme LLC, with 450 participants planned, started 2019-12-19 and due to reach its primary completion in 2032-02-13. Interventions recorded: Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed, Vibostolimab and Boserolimab.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD), Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Merck & Co. (MSD), Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Merck & Co. (MSD), Carboplatin, Pembrolizumab and the tag pipeline.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
Shares Pemetrexed, Carboplatin, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pemetrexed, Carboplatin, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.